Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics, Inc.'s stock has experienced fluctuations, increasing by 113.74% over the last 12 months but decreasing by 20.90% in the past month. On December 19, 2025, the stock declined by 28.90% following an FDA regulatory update, and after reporting earnings on November 14, 2025, the stock price drifted 45.7% lower over the subsequent 67 days. Insider trading activity has been observed, with key executives selling shares in early January 2026.

As a clinical-stage biopharmaceutical company, Galectin Therapeutics, Inc.'s revenue generation is primarily driven by its research and development activities, progress in clinical trials, and potential future regulatory approvals and commercialization of its drug candidates. The demand for its products and services is not subject to typical seasonal fluctuations.

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for chronic liver disease and cancer, operating within the Biotechnology & Medical Research sector. Their primary product candidate, belapectin (GR-MD-02), targets galectin-3 protein and is in Phase 2b/3 clinical trials for MASH with cirrhosis, holding Fast Track designation from the FDA. Belapectin is also in Phase 2 trials for liver fibrosis, severe skin disease, and as a combination immunotherapy for advanced cancers, with patent protection through 2032.

Galectin Therapeutics, Inc. is headquartered in Norcross, Georgia, USA, with primary operations focused on research and development and clinical trials conducted in various locations. The company does not have a broad international commercial geographic footprint for product distribution, as its lead product is still in clinical development.

Galectin Therapeutics, Inc.'s brand reputation has been impacted by ongoing investigations from multiple law firms regarding potential fraud, which can negatively affect public perception and investor confidence. Consistent insider selling activity by key executives could also be viewed unfavorably by the market and impact the company's reputation.

Galectin Therapeutics Inc. has a diverse ownership structure, with individual investors holding 54% of the stock, insiders owning 20%, and hedge funds holding 8.7%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Geode Capital Management, Llc. Richard Uihlein is the largest individual shareholder, holding 16% of the shares, while CEO Joel Lewis holds 1.3%.